Sickle Cell Disease Clinical Trial
Official title:
A Multi-center, Randomized, Double Blind, Dose Escalation Safety Study of MP4CO in Clinically Stable Adult Sickle Cell Patients
Sickle Cell Anemia is caused by an inherited hemoglobin disorder. Healthy red blood cells
are discoid and can deform and move through small blood vessels to carry oxygen to all parts
of the body. In sickle cell disease, as red blood cells circulate and oxygen is released in
the circulatory system, the deoxygenated abnormal hemoglobin S can begin to polymerize. When
this occurs, the red blood cells can become sticky and elongated. These sickled red blood
cells are less flexible and will obstruct small blood vessels and block normal red blood
cells from traveling through the circulatory system, which limits oxygen delivery to tissues
and organs. This is known as a "sickle crisis".
Patients suffering from a sickle crisis experience severe pain and are at risk of stroke,
heart attack or even death. By lowering the level of oxygen pressure at which sickling
occurs and opening the vasculature and rapidly delivering oxygen directly to ischemic
tissues, the addition of MP4CO to existing treatment protocols may alleviate pain associated
with a sickle cell crisis, abort a crisis and/or potentially reduce the duration of a
crisis. This could mean less time in the hospital and an improved quality of life for
patients with sickle cell anemia.
Status | Completed |
Enrollment | 32 |
Est. completion date | December 2012 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adult male or female patients (18 years of age or older) with diagnosed sickle cell disease based on Hb SS, or S/ß0 Thalassemia genotype, who are clinically stable and not experiencing an acute episode of pain Exclusion Criteria: - At least 4 painful VOCs within the preceding year requiring hospital treatment - Urgent care facility, hospital treatment or admission for treatment of a painful VOC within the previous 2 months - History of a painful VOC lasting longer than 2 weeks or > 12 pain episodes requiring intervention in a medical facility (emergency room, urgent care or clinic) in preceding year - Baseline VAS pain score = 4 cm - Hemoglobin < 6 g/dL - Transfusion of packed red blood cells within previous 4 weeks - Currently on iron chelation therapy - History of sickle cell disease-attributed CNS disease (including a) recent or past history of stroke; b) ongoing treatment with chronic transfusion therapy to prevent stroke; c. history of seizures or epilepsy; and d. evidence of or known overt cerebral vasculopathy or known cerebral vessel narrowing - Evidence of pulmonary hypertension, based on an estimated systolic pulmonary artery pressure > 25 mmHg calculated from TRJ velocity from a transthoracic echocardiography (TTE) assessment at Screening visit or from a previous TTE assessment if it was done within 1 year prior to randomization - Baseline oxygen saturation by pulse oximetry = 90% - History of a priapism within the last year - History of hypertension requiring anti-hypertensive therapy - Baseline bradycardia (heart rate < 60/min) - History of myocardial infarction, myocardial ischemia, or angina - Renal dysfunction or creatinine level within past 6 weeks of = 1.2 mg/dL (= 106 µmol/L) or a urine protein/creatinine ratio (PCR) > 50 mg/mmol - Hepatic dysfunction (AST or GGT > 3x ULN, or ALT >2x ULN, or conjugated bilirubin > 2x patient's baseline within the last 6 weeks) - Positive pregnancy test - Any acute or chronic condition which would limit the patient's ability to complete the study - Evidence of, or known to be chronically abusing illegal drugs or excessive quantities of alcohol - Known to have HIV, or active Hepatitis B or C infection, or tuberculosis - Received any other investigational drug(s) within 30 days prior to randomization - Professional or ancillary personnel involved with this study or in the employment of the investigator |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Country | Name | City | State |
---|---|---|---|
France | Hôpital Henri Mondor | Creteil | |
Jamaica | Sickle Cell Unit, University of West Indies | Kingston | |
Lebanon | Rafic Hariri University Hospital | Beirut | |
United Kingdom | Guy's Hospital | London | |
United Kingdom | King's College London | London |
Lead Sponsor | Collaborator |
---|---|
Sangart |
France, Jamaica, Lebanon, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | No efficacy evaluations will be made in this safety study | 28 days | No | |
Secondary | Adverse events | From 0 hrs after dosing through 28 Day Follow-up visit | Yes | |
Secondary | Vital signs | Blood pressure, heart rate, respiration, temperature | Baseline, Hourly from 0 - 8 hours, 24, 48, and 72 hours, and at 7 days | Yes |
Secondary | Laboratory assessments | Hematology, serum chemistry, urinalysis, renal function and biomarkers | Baseline, 24, 48, and 72 hours, and at 7 days | Yes |
Secondary | Pain levels | Patient self-assessment of pain levels using Visual Analogue Scale | Baseline, Hourly from 0 - 8 hours, 24, 48, and 72 hours, and at 7 days | No |
Secondary | Pulmonary artery pressure assessment | Trans-thoracic Echocardiography (TTE) | Baseline, Pre-infusion, 1 hour post-infusion | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02227472 -
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
|
||
Recruiting |
NCT06301893 -
Uganda Sickle Surveillance Study (US-3)
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02522104 -
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
|
Phase 4 | |
Recruiting |
NCT04688411 -
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
|
N/A | |
Terminated |
NCT03615924 -
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
|
Phase 3 | |
Not yet recruiting |
NCT06300723 -
Clinical Study of BRL-101 in Severe SCD
|
N/A | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT04917783 -
Health Literacy - Neurocognitive Screening in Pediatric SCD
|
N/A | |
Completed |
NCT02580565 -
Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
|
||
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04388241 -
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
|
N/A | |
Recruiting |
NCT05431088 -
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
|
Phase 2/Phase 3 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Withdrawn |
NCT02960503 -
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02567695 -
A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02620488 -
A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease
|
N/A | |
Completed |
NCT02565082 -
Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients
|
N/A |